---
title: Improve walking confidence through imagery
nct_id: NCT07193355
phase: NA
status: RECRUITING
sponsor: Kahramanmaras Sutcu Imam University
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07193355"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07193355"
last_fetched: "2026-05-10T14:07:45.416Z"
source: "Parkinson's Pathways (curated)"
---
# Improve walking confidence through imagery

**Goal (in five words):** Improve walking confidence through imagery

**Official Title:** Effects of Motor Imagery Training on Kinesiophobia, Gait, and Balance in Parkinson's Disease Patients

**Trial ID:** [NCT07193355](https://clinicaltrials.gov/study/NCT07193355)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Kahramanmaras Sutcu Imam University
- **Target Enrollment:** 50 participants
- **Start Date:** 2025-07-01
- **Completion Date:** 2026-07-15
- **Conditions:** PARKINSON DISEASE (Disorder), Mental Imagery, Gait Balance
- **Interventions:** Mental Imagery Application Protocol
- **Intervention Types:** OTHER

## Summary For Families

The goal is to reduce fear of movement, called kinesiophobia, and to improve walking and balance for people with Parkinson's who feel unsteady or hesitant to move. The approach uses a guided mental imagery protocol, where you rehearse walking, turning, and balance tasks in your mind to activate the same motor brain circuits as real movement, helping retrain patterns and build confidence; because it is non-drug, it can be done alongside medications like levodopa without interfering with them. Looking for adults 40 to 75 with idiopathic Parkinson's at Modified Hoehn and Yahr stage 4 or lower, who meet cognitive screening (MMSE ≥22 with formal training, or ≥18 without), have no other neurological or systemic disease, and no upper extremity contractures; people with treated psychiatric illness, on neuroleptics or antidepressants, or with certain orthopedic or rheumatologic conditions are excluded. Enrollment is 50 participants, starting July 2025.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Individuals aged 40-75 diagnosed with idiopathic PD, with a Modified Hoehn \& Yahr (m-HY) scale stage ≤4, and a score of ≥22 on the Mini Mental State Examination for those with formal training and ≥18 for those without formal training;
* Individuals with no other known neurological and/or systemic disease;
* Individuals without any upper extremity contractures;

Exclusion Criteria:

* Individuals with diagnosed and/or treated psychiatric illnesses;
* Individuals who are taking neuroleptic medications or antidepressants;
* Individuals with orthopedic conditions such as severe dyskinesia, carpal tunnel syndrome, tendon injuries, and finger amputations that interfere with manual dexterity tests; rheumatological conditions such as rheumatoid arthritis and osteoarthritis; and individuals with any neurological disease other than PD.
```

## Locations (1)

- Kahramanmaraş Sütçü imam University, Kahramanmaraş, Onikişubat, Turkey (Türkiye) _(37.5847, 36.9264)_
  - hatice adıgüzel tat, associate professor — (CONTACT) — +903443002647 — fzthatis@gmail.com
  - (CONTACT) — fzthatis@gmail.com
  - hatice adıgüzel tat, Associate Professor — (SUB_INVESTIGATOR)
  - asiya uzun, Asisstant Prof — (PRINCIPAL_INVESTIGATOR)
  - Yusuf Şinasi Kırmacı, Asisstant Prof — (SUB_INVESTIGATOR)
  - abdulkadir öztürk, msc — (SUB_INVESTIGATOR)
  - Tuğçe Simay Özbay, msc — (SUB_INVESTIGATOR)
  - Buket Tuğan yıldız, Associate Professor — (SUB_INVESTIGATOR)
  - Deniz Tuncel Berktaş, Proffessor — (SUB_INVESTIGATOR)
  - Zekiye İpek katırcı kırmacı, Associate Professor — (SUB_INVESTIGATOR)

## Central Contacts

- hatice adıgüzel tat, Associate Proffessor — (CONTACT) — +903443002647 — fzthatis@gmail.com
- hatice Adiguzel tat, Associate Proffessor — (CONTACT) — fzthatis@gmail.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT07193355*  
*HTML version: https://parkinsonspathways.com/trial/NCT07193355*  
*Source data: https://clinicaltrials.gov/study/NCT07193355*